Chelsea Therapeutics to Host Conference Call to Discuss Acquisition by Lundbeck
08 May 2014 - 9:58PM
Chelsea Therapeutics International, Ltd. (Chelsea) (Nasdaq:CHTP), a
biopharmaceutical development company, has entered into a
definitive agreement to be acquired by H. Lundbeck A/S (Lundbeck)
(LUN.CO) (LUN DC) (HLUYY), a global pharmaceutical company that
specializes in brain diseases. The details of this transaction can
be found in the joint press release issued by the two companies.
Chelsea Therapeutics' Joseph G. Oliveto, President and Chief
Executive Officer, will host a conference call at 9:00 a.m. EDT to
discuss the transaction.
To listen to the call, dial (844) 825-0511(domestic) or (708)
290-1372 (international) and enter conference ID 44456258. Please
dial in at least five minutes before the scheduled start
time. A replay of the call will be available through May 15,
2014, by dialing (855) 859-2056 (domestic) or (404) 537-3406
(international) and entering the passcode 44456258.
The conference call also will be available in the investor
relations section of the Company's website,
http://chtp.client.shareholder.com/index.cfm.
About Chelsea Therapeutics
Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical
development company that acquires, develops and commercializes
innovative products for the treatment of a variety of human
diseases, including central nervous system disorders. Chelsea
acquired global development and commercialization rights to
droxidopa (L-DOPS), or NORTHERA, from Dainippon Sumitomo Pharma
Co., Ltd. in 2006, excluding Japan, Korea, China and Taiwan. For
more information about the Company, visit
www.chelseatherapeutics.com.
Notice to Investors
The tender offer (the "Offer") in connection with the
transaction has not yet commenced, and this document is neither an
offer to purchase nor a solicitation of an offer to sell any shares
of the common stock of Chelsea or any other securities. On the
commencement date of the Offer, Lundbeck will file a Tender Offer
Statement on Schedule TO, including an offer to purchase, a letter
of transmittal and related documents, with the SEC and thereafter
Chelsea will file a Solicitation/Recommendation Statement on
Schedule 14D-9 with the SEC. Investors and security holders are
urged to read both the Tender Offer Statement and the
Solicitation/Recommendation Statement regarding the Offer, as they
may be amended from time to time, when they become available
because they will contain important information. Investors and
security holders may obtain a free copy of these statements (when
available) and other documents filed with the SEC at the website
maintained by the SEC at www.sec.gov or by directing such requests
to the Information Agent for the tender offer which will be named
in the Tender Offer Statement. Copies of Chelsea's filings with the
SEC may also be obtained free of charge at the "Investors" section
of Chelsea's website at www.chelseatherapeutics.com.
Safe Harbor/Forward-Looking Statements
The above information contains forward-looking statements that
provide our expectations or forecasts of future events such as the
tender offer and transactions contemplated by the merger agreement,
new product introductions, product approvals and financial
performance.
Such forward-looking statements are subject to risks,
uncertainties and inaccurate assumptions. This may cause actual
results to differ materially from expectations and it may cause any
or all of our forward-looking statements here or in other
publications to be wrong. Factors that may affect future results
include interest rate and currency exchange rate fluctuations,
delay or failure of development projects, production problems,
unexpected contract breaches or terminations, government-mandated
or market-driven price decreases for our products, introduction of
competing products, our ability to successfully market both new and
existing products, exposure to product liability and other
lawsuits, changes in reimbursement rules and governmental laws and
related interpretation thereof, unexpected growth in costs and
expenses, the possibility that the transaction may not be
consummated or that the expected benefits of the transaction may
not materialize as expected, Lundbeck's and Chelsea's ability to
timely complete the transaction, if at all, or to, prior to the
completion of the transaction, if at all, satisfy all closing
conditions, the possibility that the merger agreement may be
terminated, and the impact of the current economic environment,
fluctuations in operating results, market acceptance of NORTHERA,
and other risks that are described in Chelsea's Annual Report on
Form 10-K for the year ended December 31, 2013 and in its
subsequently filed SEC reports. Neither Lundbeck nor Chelsea
undertakes any obligation to update these forward-looking
statements except to the extent otherwise required by law.
CONTACT: Investors:
David Pitts
Argot Partners
david@argotpartners.com
+1 212-600-1902
Media:
Chuck Burgess
Abernathy MacGregor
CLB@abmac.com
+1 212 371 5999
Liz Micci
Abernathy MacGregor
EDM@abmac.com
+1 212 371 5999
H Lundbeck AS (PK) (USOTC:HLUYY)
Historical Stock Chart
From Jun 2024 to Jul 2024
H Lundbeck AS (PK) (USOTC:HLUYY)
Historical Stock Chart
From Jul 2023 to Jul 2024